Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

State of Alaska Department of Revenue cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the ...

All in all, Ingrezza pulled in $2.3 billion in 2024, making for an “all-time record growth year” for the drug, Benevich noted. Teva's Austedo, meanwhile, collected $1.6 billion in sales last year.

According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for movement disorder tardive dyskinesia). Management proffered guidance for Ingrezza ...

Does Warren Buffett Know Something That Wall Street Doesn't? The Billionaire Investor Is Piling Into a High-Yield Stock That Certain Analysts Recommend Selling. Mark Cuban's $400K Bet On Teen ...

Agnico Eagle Mines Expects Gold Production Forecast To Remain Stable At 3.30 - 3.50 Million Ounces Annually In 2025 To 2027, Consistent With 2024, And 3% Lower Than Prior Guidance In Years 2025 ...

Competition to Austedo and Xenazine is also looming from Neurocrine Biosciences, whose VMAT2 drug Ingrezza (valbenazine) is already approved to treat tardive dyskinesia with a phase 3 readout in ...